Efficacy of posaconazole in a murine model of central nervous system aspergillosis

被引：49

作者：

Imai, JK

Singh, G

Clemons, KV

Stevens, DA

机构：

[1] Santa Clara Valley Med Ctr, Div Infect Dis, Dept Med, San Jose, CA 95128 USA

[2] Calif Inst Med Res, San Jose, CA 95128 USA

[3] Stanford Univ, Dept Med, Div Infect Dis & Geog Med, Stanford, CA 94305 USA

来源：

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2004年 / 48卷 / 10期

关键词：

D O I：

10.1128/AAC.48.10.4063-4066.2004

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

Human central nervous system (CNS) aspergillosis has >90% mortality. We compared posaconazole with other antifungals for efficacy against murine CNS aspergillosis. All tested regimens of posaconazole were equivalent to those of amphotericin B and superior in prolonging survival and reducing CFU to those of itraconazole and caspofungin and to vehicle controls. No antifungal regimen effected cure. No toxicity was noted. Overall, posaconazole shows potential for treating CNS aspergillosis.

引用

页码：4063 / 4066

页数：4

共 36 条

[31]

Schwartz S., 2004, Annals of Hematology, V83, pS42

[32] In vitro antifungal activity of novel azole derivatives with a morpholine ring, UR-9746 and UR-9751, and comparison with fluconazole [J].